Inaugural Employer-Provider Interface Council Conference Explores Value in Healthcare.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 26
- By:
- Publication type:
- Article
Works matching IS 21534888 AND DT 2019 AND VI 10 AND IP 5
Results: 20
1
2
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 25
- By:
- Publication type:
- Article
3
FDA Approves Daratumumab Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 24
- Publication type:
- Article
4
Patients with Medicaid or No Insurance Have Worse Survival in Clinical Trials.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 24
- By:
- Publication type:
- Article
5
Neoantigens Are Effective Targets for Developing Cancer Vaccines.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 23
- By:
- Publication type:
- Article
6
Keytruda plus Lenvima Combo FDA Approved for Advanced Endometrial Carcinoma with No MSI-H or dMMR Tumors.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 22
- Publication type:
- Article
7
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 22
- By:
- Publication type:
- Article
8
Financial Toxicity High for Low-Income Patients in Early-Phase Clinical Trials.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 21
- By:
- Publication type:
- Article
9
Lost Earnings from Cancer-Related Deaths Cost the United States $94 Billion in 2015.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 20
- Publication type:
- Article
10
Formal Hereditary Cancer Genetics Counseling Improves Patient Outcomes.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 20
- By:
- Publication type:
- Article
11
Patient-Centered Clinical Pathways Should Incorporate the Patient's Voice.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 19
- Publication type:
- Article
12
FDA Approved Erleada for Metastatic Castration-Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 18
- Publication type:
- Article
13
Inrebic Receives FDA Approval for Adults with Myelofibrosis.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 18
- Publication type:
- Article
14
Delivering High-Value Personalized Interventions.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 11
- By:
- Publication type:
- Article
15
Rozlytrek Third FDA-Approved Tumor-Agnostic Drug and Second Treatment for Patients with NTRK Fusion Tumors.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 9
- Publication type:
- Article
16
Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 8
- Publication type:
- Article
17
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 1
- By:
- Publication type:
- Article
18
Oral Cancer and Sex in the Era of HPV Infection.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 1
- By:
- Publication type:
- Article
19
Nubeqa New Oral Therapy FDA Approved for Nonmetastatic Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 1
- Publication type:
- Article
20
Oral Parity Laws Could Reduce Disparities in Cancer Care.
- Published in:
- Value-Based Cancer Care, 2019, v. 10, n. 5, p. 1
- By:
- Publication type:
- Article